NIAGEN BIOSCIENCE INC
NAGENASDAQ🏆 #3580 by market capEarnings Nov 2US Equity
$752.40▼ $29.80 (−3.96%)
Simulated priceTrack NAGE
Get earnings, price moves & breaking news on Telegram
24h▼ 4.0%
7d▲ 24171.0%
14d▲ 24896.7%
30d▲ 22700.0%
ytd▲ 11748.8%
1y▲ 7503.8%
🏦Market Cap
$243M
Small Cap
📈Revenue Growth (YoY)
+29.9%
High Growth
📊Gross Margin
64.2%
High
💵FCF Margin
4.4%
Moderate
⚖️P/S Ratio
1.9x
Cheap
Otter Score
76
Good
Trading Snapshot
- Day Range
- $742.41 – $762.57
- 52-Week Range
- $2.87 – $10.06
- Volume
- $2.15B
- Avg Volume
- $1.61B
- Shares Outstanding
- 79.6M
- Next Earnings
- Dec 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $129M
- Last Q Revenue
- $30M
- P/E Ratio
- 15.7
- P/S Ratio
- 1.9x
- EPS (TTM)
- $0.20
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +3.4%
Why Investors Own NAGE
- ✓High-growth profile — revenue up +54.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NIAGEN BIOSCIENCE INC
NAGEFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$129M▲ +29.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.3%▲ +3.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$14M▲ +85.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$13M▲ +10.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
84.4M▲ +3.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$62M▲ +$20M YoY
StockOtter · stockotter.spaceAbout NIAGEN BIOSCIENCE INC
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100
Analyst Price Target
ⓘAverage Target
$1,001.62
▲ +33.1% Upside
High Target$1,158.52
Low Target$873.57
Based on 22 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
NIAGEN BIOSCIENCE INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift NAGE price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
NIAGEN BIOSCIENCE INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.